309 related articles for article (PubMed ID: 2536413)
1. Inhibition of platelet-activating factor (PAF)-induced chemotaxis and PAF binding to human eosinophils and neutrophils by the specific ginkgolide-derived PAF antagonist, BN 52021.
Kurihara K; Wardlaw AJ; Moqbel R; Kay AB
J Allergy Clin Immunol; 1989 Jan; 83(1):83-90. PubMed ID: 2536413
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of neutrophil and eosinophil induced chemotaxis by nedocromil sodium and sodium cromoglycate.
Bruijnzeel PL; Warringa RA; Kok PT; Kreukniet J
Br J Pharmacol; 1990 Apr; 99(4):798-802. PubMed ID: 2163279
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of platelet-activating factor- and zymosan-activated serum-induced chemotaxis of human neutrophils by nedocromil sodium, BN 52021 and sodium cromoglycate.
Bruijnzeel PL; Warringa RA; Kok PT
Br J Pharmacol; 1989 Aug; 97(4):1251-7. PubMed ID: 2551444
[TBL] [Abstract][Full Text] [Related]
4. Inhibition by BN 52021 (ginkgolide B) of the binding of [3H]-platelet-activating factor to human neutrophil granulocytes.
Földes-Filep E; Braquet P; Filep J
Biochem Biophys Res Commun; 1987 Nov; 148(3):1412-7. PubMed ID: 2825685
[TBL] [Abstract][Full Text] [Related]
5. Inhibitory effects of nedocromil sodium on the in vitro induced migration and leukotriene formation of human granulocytes.
Bruijnzeel PL; Warringa RA; Kok PT; Hamelink ML; Kreukniet J
Drugs; 1989; 37 Suppl 1():9-18; discussion 69-77. PubMed ID: 2547570
[TBL] [Abstract][Full Text] [Related]
6. Effects of nedocromil sodium on in vitro induced migration, activation, and mediator release from human granulocytes.
Bruijnzeel PL; Warringa RA; Kok PT; Hamelink ML; Kreukniet H; Koenderman L
J Allergy Clin Immunol; 1993 Jul; 92(1 Pt 2):159-64. PubMed ID: 8393021
[TBL] [Abstract][Full Text] [Related]
7. Effects of platelet activating factor on the chemotaxis of normodense eosinophils from normal subjects.
Tamura N; Agrawal DK; Suliaman FA; Townley RG
Biochem Biophys Res Commun; 1987 Feb; 142(3):638-44. PubMed ID: 3030295
[TBL] [Abstract][Full Text] [Related]
8. Generation of an eosinophilotactic activity in the pleural cavity of platelet-activating factor-injected rats.
e Silva PM; Martins MA; Faria Neto HC; Cordeiro RS; Vargaftig BB
J Pharmacol Exp Ther; 1991 Jun; 257(3):1039-44. PubMed ID: 2046020
[TBL] [Abstract][Full Text] [Related]
9. Differential effects of the PAF receptor antagonist UK-74,505 on neutrophil and eosinophil accumulation in guinea-pig skin.
Sanz MJ; Weg VB; Walsh DT; Williams TJ; Nourshargh S
Br J Pharmacol; 1994 Oct; 113(2):513-21. PubMed ID: 7834203
[TBL] [Abstract][Full Text] [Related]
10. Effects of nedocromil sodium and WEB 2086 on chemoattractant-stimulated neutrophil migration through cellular and noncellular barriers.
Carolan EJ; Casale TB
Ann Allergy; 1992 Oct; 69(4):323-8. PubMed ID: 1329582
[TBL] [Abstract][Full Text] [Related]
11. Comparison of three paf-acether receptor antagonist ginkgolides.
Korth R; Nunez D; Bidault J; Benveniste J
Eur J Pharmacol; 1988 Jul; 152(1-2):101-10. PubMed ID: 2850196
[TBL] [Abstract][Full Text] [Related]
12. The effect of WEB 2086 on PAF-induced eosinophil chemotaxis and LTC4 production from eosinophils.
Miyagawa H; Nabe M; Hopp RJ; Okada C; Bewtra AK; Townley G
Agents Actions; 1992 Sep; 37(1-2):39-43. PubMed ID: 1456179
[TBL] [Abstract][Full Text] [Related]
13. The inhibitory effect of methotrexate on PAF-induced neutrophil and eosinophil locomotion in asthmatic patients.
Tsai JJ; Wang TF; Wang SR
Asian Pac J Allergy Immunol; 1994 Jun; 12(1):65-71. PubMed ID: 7872994
[TBL] [Abstract][Full Text] [Related]
14. The effect of nedocromil sodium on human eosinophil activation.
Moqbel R; Cromwell O; Kay AB
Drugs; 1989; 37 Suppl 1():19-22; discussion 69-77. PubMed ID: 2547563
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of receptor-mediated platelet activation by nedocromil sodium.
Roth M; Solèr M; Lefkowitz H; Emmons LR; Anstine D; Hornung M; Perruchoud AP
J Allergy Clin Immunol; 1993 Jun; 91(6):1217-25. PubMed ID: 8389778
[TBL] [Abstract][Full Text] [Related]
16. Triflavin potentiates the antiplatelet activity of platelet activating factor receptor antagonist on activated neutrophil-induced platelet aggregation.
Lee LW; Peng HC; Ko WC; Hung WC; Su CH; Lin CH; Huang TF; Yen MH; Sheu JR
Eur J Pharmacol; 1999 Jan; 364(2-3):239-46. PubMed ID: 9932729
[TBL] [Abstract][Full Text] [Related]
17. Effects of platelet activating factor receptor antagonists on intracellular platelet activating factor function in neutrophils.
Koike H; Imanishi N; Natsume Y; Morooka S
Eur J Pharmacol; 1994 Nov; 269(3):299-309. PubMed ID: 7895770
[TBL] [Abstract][Full Text] [Related]
18. Chemotactic effect of PAF-acether on peritoneal eosinophils from normal rats.
Martins MA; Etienne A; Soulard C; Domingo MT; Braquet P
Braz J Med Biol Res; 1989; 22(9):1151-4. PubMed ID: 2636011
[TBL] [Abstract][Full Text] [Related]
19. Activation of guinea pig eosinophils by human recombinant IL-5. Selective priming to platelet-activating factor-acether and interference of its antagonists.
Coëffier E; Joseph D; Vargaftig BB
J Immunol; 1991 Oct; 147(8):2595-602. PubMed ID: 1655895
[TBL] [Abstract][Full Text] [Related]
20. Platelet-activating factor (PAF)-induced chemotaxis and PAF binding to human eosinophils.
Fukuda T; Numao T; Akutsu I; Makino S
J Lipid Mediat; 1992; 5(2):145-9. PubMed ID: 1525356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
